Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, noninferiority clinical trial of Single-Shot Intrathecal Morphine versus Continuous Wound Infiltration for postoperative pain control after open pancreatoduodenectomy.

The British journal of surgery·2026
Same author

Real-World Application of a Machine Learning-Based Early Recurrence Model for Guiding Adjuvant Chemotherapy Use in Patients with Gallbladder Cancer.

Gut and liver·2026
Same author

How much pancreas is too much?: optimal pancreas resection volume to prevent diabetes mellitus after left-sided pancreatectomy.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy.

Yonsei medical journal·2026
Same author

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

BMC cancer·2026
Same author

Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal adenocarcinoma.

Surgical oncology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 9, 2026

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.3K

Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of

Won-Gun Yun1,2, Wooil Kwon3, Hee Ju Sohn4

  • 1Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

Annals of Surgical Oncology
|April 30, 2025
PubMed
Summary
This summary is machine-generated.

For pancreatic head cancer, achieving a wide resection margin improves survival after upfront surgery. In contrast, a narrow margin may suffice after neoadjuvant chemotherapy, with radiotherapy beneficial for margin involvement.

More Related Videos

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

3.6K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

672

Related Experiment Videos

Last Updated: Jul 9, 2026

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.3K
Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
04:45

Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way

Published on: May 10, 2021

3.6K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

672

Area of Science:

  • Surgical Oncology
  • Gastrointestinal Oncology
  • Radiation Oncology

Background:

  • Pancreatic head cancer treatment focuses on margin status and perioperative strategies.
  • The role of resection margins and radiotherapy in neoadjuvant chemotherapy (NAC) settings is not fully understood.
  • This study investigates the prognostic significance of margin status and perioperative radiotherapy.

Purpose of the Study:

  • To evaluate the prognostic impact of resection margin status (R0-wide, R0-narrow, R1) in pancreatic head cancer.
  • To assess the influence of perioperative radiotherapy on outcomes.
  • To compare findings in upfront surgery versus neoadjuvant chemotherapy settings.

Main Methods:

  • Retrospective analysis of 307 patients undergoing upfront pancreaticoduodenectomy (PD) and 97 undergoing NAC followed by PD (2014-2019).
  • Classification of resection margins: R0-wide (≥1 mm), R0-narrow (0-1 mm), R1 (=0 mm).
  • Multivariate analyses to identify prognostic factors for overall survival and locoregional recurrence.

Main Results:

  • In upfront surgery, 5-year OS rates decreased with margin status: R0-wide (39.1%), R0-narrow (25.6%), R1 (12.5%).
  • In NAC settings, 5-year OS rates also decreased: R0-wide (52.2%), R0-narrow (45.5%), R1 (8.3%), with no significant difference between R0-wide and R0-narrow.
  • Concurrent chemoradiotherapy after surgery significantly reduced locoregional recurrence risk in both settings.

Conclusions:

  • A wide resection margin (R0-wide) may improve prognosis in upfront surgery for pancreatic head cancer.
  • A narrow margin (R0-narrow) might be acceptable following neoadjuvant chemotherapy.
  • Adjuvant radiotherapy should be considered, especially for patients with margin involvement (R1).